PHESGO

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Lithuania, Netherlands, Nigeria, Poland, Romania, South Africa, UK.

Active ingredients

The drug PHESGO contains a combination of these active pharmaceutical ingredients (APIs):

1	Pertuzumab UNII K16AIQ8CTM - PERTUZUMAB
	Pertuzumab is a recombinant humanised monoclonal antibody that specifically targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). Pertuzumab inhibits ligand-initiated intracellular signalling through two major signal pathways, mitogen-activated protein (MAP) kinase and phosphoinositide 3-kinase (PI3K). Inhibition of these signalling pathways can result in cell growth arrest and apoptosis, respectively.
	Read more about Pertuzumab
2	Trastuzumab UNII P188ANX8CK - TRASTUZUMAB
	Trastuzumab is a recombinant humanised IgG1 monoclonal antibody against the human epidermal growth factor receptor 2 (HER2). Τrastuzumab has been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumour cells that overexpress HER2.
	Read more about Trastuzumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
PHESGO Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FY01		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FY Combinations of monoclonal antibodies and antibody drug conjugates
Discover more medicines within L01FY01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	195-MBE-0521, 196-MBE-0521
EE	Ravimiamet	1835995, 1836008
FI	Lääkealan turvallisuus- ja kehittämiskeskus	438330, 535672
FR	Base de données publique des médicaments	63806777, 67178992
GB	Medicines & Healthcare Products Regulatory Agency	393038, 393041
HK	Department of Health Drug Office	67118, 67119
IL	מִשְׂרַד הַבְּרִיאוּת	9030, 9031
IT	Agenzia del Farmaco	049288018, 049288020
LT	Valstybinė vaistų kontrolės tarnyba	1091695, 1091696
NG	Registered Drug Product Database	A6-100047, A6-100063
Switch country to Nigeria in order to find specific presentations of PHESGO
NL	Z-Index G-Standaard, PRK	207306, 207322
PL	Rejestru Produktów Leczniczych	100443830, 100443846
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W67286001, W67296001
US	FDA, National Drug Code	50242-245, 50242-260
ZA	Health Products Regulatory Authority	55/30.1/0444, 55/30.1/0445